By Andrea Figueras
Dow Jones-Roche has achieved an approval success in the United States. As the Swiss pharmaceutical company announced, the health authority FDA has approved a test to recognize a certain form of breast cancer.
The FDA had approved an extension of the “Pathway Her2 (4B5)” test to identify patients with HR-positive, her2-ultran-reduced, metastatic breast cancer, for which treatment with the antibody conjugate is enertu. Enhaltu has been discovered by Daiichi Sankyo and is developed by the Japanese company together with Straweneca.
Contact with the author: [email protected]
DJG/DJN/MGO/ROS
(End) Dow Jones Newswires
January 31, 2025 12:36 ET (17:36 GMT)
Selected leverage products on Roche
With knock-outs, speculative investors can participate disproportionately in price movements. Simply choose the desired lever and we will show you suitable open-end products on Roche
The lever must be between 2 and 20
Advertising
